Drug Trial Radar · NCT07871435
GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
Oct 12, 2026
Primary completion
Mar 31, 2029
Study completion Sep 30, 2029
Sponsor
- Lead sponsor
- GI Innovation, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Janssen Research & Development, LLC
- First posted
- Oct 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in adult men with metastatic castration-resistant prostate cancer (mCRPC) whose cancer has progressed after previous treatment with a novel hormonal therapy (NHT).
Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions
GI-102Drug
GI-102 will be administered in accordance with the procedures specified in the study protocol.
PasritamigDrug
Pasritamig will be administered in accordance with the procedures specified in the study protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and nature of DLTs (Safety run-in phase)Time frame: From Day -14 to Cycle 1 Day 22 (35 days)
- Incidence, nature, and severity of AEs graded according to CTCAE v6.0 (Safety run-in phase)Time frame: Up to 2 years
- PSA response rate (≥ 50% decline from baseline) per PCWG3 (Expansion phase)Time frame: Up to 2 years
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Columbia University Medical Center
New York, New York · Not yet recruiting
Yonsei University Health System, Severance Hospital
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea Seoul ST.MARY'S Hospital
Seoul, Banpo-daero, South Korea · Recruiting
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea · Recruiting
Ewha Womans University Mokdong Hospital
Seoul, Yangcheon-gu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.